Tag: Doses

Categories
Health

White Home lays out plan to share tens of millions of doses with poorer nations

White House lays out plan to share millions of doses with poorer nations

The Oxford-AstraZeneca covid vaccine.

Karwai Tang | Getty Images

The U.S. government will share the majority of its donated Covid-19 vaccine doses through COVAX, the World Health Organization-led program that provides shots to countries in need, the White House announced Thursday.

The Biden administration has committed to donating at least 20 million doses of Covid vaccines produced by Pfizer-BioNTech, Moderna and Johnson & Johnson as well as 60 million doses of AstraZeneca’s vaccines, which has not yet been authorized for use in the United States.

The U.S. plans to allocate 75% of the vaccines through the COVAX global vaccine sharing program, the White House in an email. Of the first 25 million doses, about 6 million will go to countries in South and Central America, 7 million to Asia and 5 million to Africa, the White House said. About 6 million will go to neighboring countries and U.S. allies.

At least 25% of shots will be kept for immediate U.S. needs and for “countries in need, those experiencing surges, immediate neighbors, and other countries that have requested immediate U.S. assistance,” according to the plan.

The administration is donating the shots to “save lives” and thwart the emergence of new variants,  national security advisor Jake Sullivan said Thursday.

“The United States is not doing this as some kind of back-and-forth deal where we are getting something in return,” Sullivan said at a White House briefing. “We are giving these for a single purpose. It is the purpose of ending this pandemic.”

The announcement comes as world leaders urge wealthy nations such as the U.S. to donate Covid shots to other countries. While the U.S. has returned to some form of normality as more Americans get vaccinated and new cases fall, other countries, like India, have experienced huge outbreaks.

Just last week, the WHO said Africa needed at least 20 million doses of AstraZeneca’s vaccine within six weeks to get the second round of shots to people who have received the first.

The head of the Coalition for Epidemic Preparedness Innovations told Reuters that leaders of the Group of 7 rich nations must donate shots urgently to avoid an outcome akin to the 1918 flu pandemic, which killed 50 million people.

“It’s a moral imperative if we want to avoid situations like Peru, if we want to avoid impacts that could rival those of the 1918 flu, we must send vaccine to countries to protect their health-care workers and protect the vulnerable populations now,” Richard Hatchett, chief executive of CEPI which co-runs the COVAX vaccine sharing facility, told Reuters.

In addition to donating the doses, the White House also announced it is lifting restrictions as part of the Defense Production Act that gave the U.S. priority for vaccines developed by AstraZeneca, Sanofi and Novavax.

Categories
Health

U.S. begins research testing mix-and-match Covid vaccine doses

U.S. begins study testing mix-and-match Covid vaccine doses

A healthcare doctor prepares a dose of Johnson & Johnson’s Coronavirus Disease (COVID-19) vaccine for a commuter during the opening of MTA’s public vaccination program on the 179th Street subway station in the Queens borough of New York City in front. USA, May 12, 2021.

Shannon Stapleton | Reuters

The National Institutes of Health announced Tuesday that they had started an early-stage clinical trial looking into what happens when an adult fully vaccinated with a type of Covid-19 vaccine like Pfizer’s is boosted with another vaccination about three to four months later.

The study will enroll approximately 150 adults who have received any of the three Covid vaccination regimens currently available under the Food and Drug Administration’s emergency approval: Johnson & Johnsons, Moderna, or Pfizer.

Federal health officials said people who have not yet received an approved vaccine are also eligible to enroll in a separate group for the study. These volunteers will receive two doses of the vaccine from Moderna and will receive a booster dose of one of the three vaccines around 12 to 20 weeks later, officials said.

“Although the vaccines currently approved by the US Food and Drug Administration offer strong protection against COVID-19, we must prepare for the possibility that booster vaccinations will be required to counter declining immunity and step up with an evolving virus said Dr Fauci, director of the National Institute of Allergy and Infectious Diseases, a member of the NIH.

“The results of this study are intended to inform public health policy decisions about the potential use of mixed vaccination schedules in the event that booster doses are indicated,” he added.

The study is taking place as drug makers and some scientists are now saying that people will likely need a booster dose of the Covid-19 vaccines and possibly additional vaccinations every year, just like they did with seasonal flu.

Pfizer and Moderna’s Covid-19 vaccines currently require two doses three to four weeks apart, while Johnson & Johnson vaccines only require one prick. All three vaccines have been shown to be highly effective against Covid, although company executives now expect this strong protection to wear off over time.

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said last month that Covid-19 booster vaccinations could be required for fully vaccinated individuals within a year.

“So, hopefully, you know, it would be nice if it turned out it would be a year before someone needed a refresher,” said Marks on the 18th of school and junior journalists.

“But we still don’t know,” he added. “It could be more, it could be a little less, but … that’s just something we need to find out over time.”

Each vaccine group in the NIH study will enroll about 25 people ages 18 to 55 and about 25 people ages 56 and older.

Twelve to 20 weeks after their initial vaccination, participants in the study will receive a single booster dose of the Moderna vaccine.

Categories
Health

Africa wants at the very least 20 million doses within the subsequent six weeks, WHO says

Africa needs at least 20 million doses in the next six weeks, WHO says

A medical worker injects a dose of the COVID-19 vaccine into a man at a hospital in Accra, capital of Ghana, on May 19, 2021.

Seth | Xinhua News Agency | Getty Images

Africa will need at least 20 million doses of AstraZeneca’s Covid-19 vaccine within the next six weeks to allow people who have already received the first round of shooting, the World Health Organization said on Thursday.

The data shows that one dose of the AstraZeneca vaccine is 70% effective for at least 12 weeks, but the second dose offers 81% protection against Covid over a longer period, according to the WHO. Antibodies have been seen in the body for up to six months after a dose.

In order for the continent to be able to vaccinate at least 10% of its population by September, another 200 million doses of an approved Covid-19 vaccine are urgently needed, according to the WHO.

As of Thursday, 28 million doses of Covid-19 had been administered in Africa by various drug manufacturers that have nearly 1.4 billion people, which is less than two doses for every 100 people on the continent. For comparison, more than 165 million people in the United States have received at least one dose of vaccine, according to the Centers for Disease Control and Prevention, almost half the country’s population.

“Africa needs vaccines now. Any break in our vaccination campaigns will result in deaths and a loss of hope,” said Dr. Matshidiso Moeti, WHO Regional Director for Africa. “We urge countries that have vaccinated their high-risk groups to speed up dose distribution to fully protect the most vulnerable.”

France has pledged to share half a million cans with six African countries over the next few weeks and has already sent 31,000 cans to Mauritania. Another 74,400 doses are to be delivered soon, the WHO announced.

The European Union has announced that it will send 100 million doses to low-income countries by the end of 2021, and the United States has pledged 80 million doses. Other countries around the world have also expressed an interest in sharing the doses. Countries in Africa that don’t use all of their cans are also sharing them with other countries on the continent, according to the WHO.

Redistributing vaccine doses is helpful, but expensive. WHO says Africa needs to increase its vaccine production capacity.

“Giving up intellectual property is a critical first step, but it needs to go hand in hand with sharing expertise and critical technologies,” the WHO wrote in a press release.

In Africa, 54 countries are involved in WHO efforts in more than 100 countries to submit a draft resolution to the World Health Assembly. The resolution aims to “strengthen local production, promote technology transfer and innovation and examine the agreement on trade-related aspects of intellectual property rights and intellectual property rights from the point of view of increasing local production,” according to the WHO.

Around 40 African countries have also followed WHO training on building production capacities. The WHO claims to be working with the African Union on a plan to support feasibility studies and technology transfers upon request.

“It’s too early to say if Africa is on the verge of a third wave. We do know, however, that cases are rising and the clock is ticking,” said Moeti.

Categories
Health

Two doses of Covid vaccines present safety in opposition to India variant

Two doses of Covid vaccines provide protection against India variant

A healthcare worker holds syringes with the Moderna and Pfizer vaccines against the coronavirus disease (COVID-19) at a vaccination centre, in El Paso, Texas, May 6, 2021.

Jose Luis Gonzalez | Reuters

A new study has found that two doses of either the Pfizer-BioNTech or AstraZeneca-University of Oxford vaccine give effective protection against the Covid variant first discovered in India, however it underscored the need for two doses, as both vaccines were significantly less effective after only one shot.

The study, led by Public Health England, also found that two doses of one of those vaccines were similarly as effective at protecting against the variant that first emerged in the U.K. and has since become a dominant strain in the West.

Dr. Jenny Harries, CEO of the U.K. Health Security Agency, told the BBC that the study provided the “first real-world evidence of vaccine effectiveness” against the variant first identified in India.

Conducted between April and May, the research found that the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617.2 Covid variant — a subtype of a variant that emerged in India last fall which has since spread to Europe — two weeks after the second dose. The vaccine was 93% effective two weeks after the second dose against the B.1.1.7 variant. which was first discovered in the U.K. last fall.

Meanwhile, two doses of the AstraZeneca vaccine were found to be 60% effective against symptomatic disease from the B.1.617.2 variant from India, compared with 66% effective against the strain from the U.K.

“Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after 2 doses compared to the B.1.1.7 (Kent) variant dominant in the U.K., and we expect to see even higher levels of effectiveness against hospitalisation and death,” the study authors wrote. The results were published Saturday as a preprint and the study has not yet been peer-reviewed.

PHE said the difference in effectiveness between the vaccines after two doses “may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer-BioNTech vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.”

However, both vaccines were only 33% effective against symptomatic disease from B.1.617.2 three weeks after the first dose. In the same time frame, they were found to be 50% effective against the B.1.1.7 variant.

Variant of concern

The variant first discovered in India has been blamed for causing a dramatic third wave of infections in the country, overwhelming hospitals and causing thousands of deaths this spring. There were concerns that Covid vaccines could be rendered less effective by the variant so the latest data should help allay those worries.

The India variant has been detected in numerous other countries now, according to the World Health Organization, which dubbed it a “variant of concern” in early May.

The PHE study analyzed data from 1,054 people, of all age groups and several ethnicities, confirmed as having the B.1.617.2 variant through genomic sequencing. The data was collected from April 5 and hence covers the period since the B.1.617.2 variant (one of three variant subtypes found in India) emerged in parts of the U.K.

“As with other variants, even higher levels of effectiveness are expected against hospitalisation and death. There are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B.1.617.2 variant. PHE will continue to evaluate this over the coming weeks,” the study’s authors added.

Responding to the study, the U.K.’s health secretary, Matt Hancock, described the findings as “groundbreaking – and proves just how valuable our Covid-19 vaccination programme is in protecting the people we love.”

The U.K. has given more than 22 million people two doses of a Covid vaccine, while 72% of the population (or almost 40 million people) have had one shot, government data shows.

Hancock said the latest data emphasized “how important the second dose is to secure the strongest possible protection” against Covid-19 and its variants.

Separate PHE analysis indicated that the country’s Covid-19 vaccination program has so far prevented 13,000 deaths and around 39,100 hospitalizations in older people in England, up to May 9.

Categories
Health

100 Million Vaccine Doses Held Up Over Contamination Issues, Emergent Reveals

Contamination Woes Hold Back 100 Million Vaccine Doses

WASHINGTON – The executive director of Emergent BioSolutions, whose Baltimore facility ruined millions of coronavirus vaccine doses, announced on Wednesday that more than 100 million doses of the vaccine were being put on hold by Johnson & Johnson as regulators screen for possible contamination.

In more than three hours of testimony before a House subcommittee, chief executive Robert G. Kramer calmly acknowledged unsanitary conditions, including mold and peeling paint, at the Baltimore plant. He acknowledged that Johnson & Johnson had discovered – not emergent – contaminated cans and fought off aggressive questions from the Democrats about his stock sales and hundreds of thousands of dollars in bonuses for company executives.

Emergent’s Bayview Baltimore facility shut down a month ago after contamination spoiled the equivalent of 15 million cans. However, Mr. Kramer told the legislature that he expected the plant to resume production “in a few days”. He said he took “very seriously” a report from federal regulators that identified manufacturing defects and assumed “full responsibility”.

“Nobody is more disappointed than us that we had to stop manufacturing new vaccines around the clock,” Kramer told the panel, adding: “I apologize for the failure of our controls.”

Mr Kramer’s appearance before the House Select Coronavirus Crisis Subcommittee, which has launched a full investigation into his company, provided the public with an initial glimpse into the men who run Emergent, a politically affiliated federal entrepreneur who has a niche market for the Biological Defense Preparation dominates with the US government as the main customer.

Mr. Kramer, who testified virtually, was assisted by Fuad El-Hibri, the company’s founder and chairman, who has grown from a small biotech company to a $ 1.5 billion company in annual sales over the past two decades has expanded. Executive compensation documents released by the subcommittee show that the company’s board of directors praised Mr. El-Hibri, who cashed in more than $ 42 million in stock and options last year, for “his critical relationships with important customers, Congress and other stakeholders. ”

Those members of Congress include Representative Steve Scalise of Louisiana, the No. 2 Republican in the House, and the Chief Republican on the House subcommittee. Federal campaign records indicate that Mr. El-Hibri and his wife have donated more than $ 150,000 to groups associated with Mr. Scalise since 2018. The company’s Political Action Committee has donated approximately $ 1.4 million to members of both parties over the past 10 years.

Mr El-Hibri expressed his remorse on Wednesday. “The cross-contamination incident is unacceptable,” he said.

Mr. Kramer’s estimate of 100 million cans held increased the number of Johnson & Johnson cans effectively quarantined due to regulatory concerns about contamination by 30 million. Federal officials had previously estimated that the equivalent of about 70 million cans – most of them for domestic use – could not be released until purity was tested.

The House Democrats began their investigation into Emergent after the New York Times documented months of problems at the Baltimore plant, including failure to properly disinfect equipment and protect it from viral and bacterial contamination.

Hours before the hearing began, the committee’s staff released confidential audits previously reported by The Times that cited repeated violations of manufacturing standards. A leading federal manufacturing expert reiterated these concerns in a June 2020 report, warning that Emergent did not have trained staff and adequate quality control in place.

“My teenage son’s room gives your facility a run for its money,” Representative Raja Krishnamoorthi, Democrat of Illinois, told Mr. Kramer.

Mr. Kramer initially stated that the contamination of the Johnson & Johnson cans “was identified by our quality control procedures and checks and balances.” However, when questioned, he admitted that a Johnson & Johnson laboratory in the Netherlands had picked up the problem. Johnson & Johnson hired Emergent to manufacture its vaccine and is now claiming greater control over the facility at the urging of the Biden government.

The federal government placed a $ 628 million contract with Emergent last year, primarily to reserve space at the Baltimore plant for vaccine manufacturing. The legislature is examining, among other things, whether the company is maintaining its contacts with a leading representative of the Trump administration, Dr. Robert Kadlec, used to secure this mandate and whether federal officials have ignored known shortcomings in placing the work on Emergent.

Mr El-Hibri told lawmakers that the government and Johnson & Johnson are aware of the risks.

“Everyone was open-minded that this is a facility that has never manufactured a licensed product before,” he said. While the Baltimore plant was “not in perfect working order – far from it,” he argued that the plant was “in the highest state of readiness” among the plants that the government had to choose from.

For Republicans, including Mr Scalise, Wednesday’s session became a means of defending Emergent and the Trump administration and raising other virus-related issues: the unproven theory that the coronavirus leaked from a laboratory in China that “Lies of the Communist Party” of China “, mask mandates and the demand of the Biden government for a renunciation of an international agreement on intellectual property.

“You are a reputable company that did Yeoman’s job protecting this bio-defense country,” exclaimed Mark E. Green, Republican of Tennessee, adding, “So you have your people a bonus for their incredible work given. “

Emergent is able to work in Washington. The board of directors is made up of former government officials, and Senate lobbying data shows the company has spent an average of $ 3 million a year on lobbying over the past decade. That’s roughly the equivalent of two pharmaceutical giants, AstraZeneca and Bristol Myers Squibb, whose annual sales are at least 17 times higher.

Democrats urged Mr. Kramer and Mr. El-Hibri to open their contacts with Dr. Kadlec, who had previously consulted for Emergent. Documents indicate that Emergent agreed to pay him $ 120,000 annually for his advisory work between 2012 and 2015 and that he recommended that Emergent be given a “priority rating” so that the contract can be approved quickly. Dr. Kadlec said he didn’t negotiate the deal but signed it.

“Did you or any other Emergent executives speak or make contacts with Dr. Kadlec while these contracts were being issued?” Representative Nydia M. Velázquez, Democrat of New York, asked Mr. Kramer.

“Congressman,” he replied cautiously, “I haven’t had any discussions with Dr. Kadlec about it.”

The government has paid Emergent $ 271 million to date, although American regulators have not yet approved a single dose of vaccine made in the vaccine in Baltimore.

An investigation by the Times found that Emergent was an oversized influence on the Strategic National Stockpile, the country’s emergency medical reserve. In a few years, the company’s anthrax vaccine made up half of the inventory budget.

The investigation found that some federal officials believed the company was undermining taxpayers – an issue that also surfaced at Wednesday’s hearing when New York Democrat Carolyn B. Maloney asked how much it would cost to make the vaccine and what he sells for. Mr. El-Hibri promised to provide the information later.

Company executives also consider their coronavirus work to be one of the “main drivers” of 2020 revenue, according to a memorandum released Wednesday by committee staff. Executives have been rewarded for what the company’s board of directors calls “exemplary overall company performance for 2020 , including a significant overachievement of the sales and earnings targets ”.

Mr Kramer received a $ 1.2 million cash bonus in 2020, the records show, and this year also sold $ 10 million worth of shares in stores that he said were planned in advance and dated Companies have been approved. Three of the company’s executive vice presidents received awards between $ 445,000 and $ 462,000.

Sean Kirk, who is responsible for overseeing development and manufacturing processes at all Emergent production sites, received a special bonus of $ 100,000 last year in addition to his regular bonus of $ 320,611, including for expanding the contract manufacturing capacities of the Company to Covid- 19 show the documents. Mr. Kirk is now on personal vacation.

Aspiring officials “appear to have wasted tax dollars while filling their own pockets,” accused Ms. Maloney.

Mr Krishnamoorthi asked Mr Kramer if he would consider giving his bonus to American taxpayers.

“I will not make this commitment,” replied Mr. Kramer.

“I didn’t think so,” replied Krishnamoorthi-san.

Rebecca R. Ruiz contributed to the coverage.

Categories
Health

Contamination Woes Maintain Again 100 Million Vaccine Doses

Contamination Woes Hold Back 100 Million Vaccine Doses

WASHINGTON – The executive director of Emergent BioSolutions, whose Baltimore facility ruined millions of coronavirus vaccine doses, announced on Wednesday that more than 100 million doses of the vaccine were being put on hold by Johnson & Johnson as regulators screen for possible contamination.

In more than three hours of testimony before a House subcommittee, chief executive Robert G. Kramer calmly acknowledged unsanitary conditions, including mold and peeling paint, at the Baltimore plant. He acknowledged that Johnson & Johnson had discovered – not emergent – contaminated cans and fought off aggressive questions from the Democrats about his stock sales and hundreds of thousands of dollars in bonuses for company executives.

Emergent’s Bayview Baltimore facility shut down a month ago after contamination spoiled the equivalent of 15 million cans. However, Mr. Kramer told the legislature that he expected the plant to resume production “in a few days”. He said he took “very seriously” a report from federal regulators that identified manufacturing defects and assumed “full responsibility”.

“Nobody is more disappointed than us that we had to stop manufacturing new vaccines around the clock,” Kramer told the panel, adding: “I apologize for the failure of our controls.”

Mr Kramer’s appearance before the House Select Coronavirus Crisis Subcommittee, which has launched a full investigation into his company, provided the public with an initial glimpse into the men who run Emergent, a politically affiliated federal entrepreneur who has a niche market for the Biological Defense Preparation dominates with the US government as the main customer.

Mr. Kramer, who testified virtually, was assisted by Fuad El-Hibri, the company’s founder and chairman, who has grown from a small biotech company to a $ 1.5 billion company in annual sales over the past two decades has expanded. Executive compensation documents released by the subcommittee show that the company’s board of directors praised Mr. El-Hibri, who cashed in more than $ 42 million in stock and options last year, for “his critical relationships with important customers, Congress and other stakeholders. ”

Those members of Congress include Representative Steve Scalise of Louisiana, the No. 2 Republican in the House, and the Chief Republican on the House subcommittee. Federal campaign records indicate that Mr. El-Hibri and his wife have donated more than $ 150,000 to groups associated with Mr. Scalise since 2018. The company’s Political Action Committee has donated approximately $ 1.4 million to members of both parties over the past 10 years.

Mr El-Hibri expressed his remorse on Wednesday. “The cross-contamination incident is unacceptable,” he said.

Mr. Kramer’s estimate of 100 million cans held increased the number of Johnson & Johnson cans effectively quarantined due to regulatory concerns about contamination by 30 million. Federal officials had previously estimated that the equivalent of about 70 million cans – most of them for domestic use – could not be released until purity was tested.

The House Democrats began their investigation into Emergent after the New York Times documented months of problems at the Baltimore plant, including failure to properly disinfect equipment and protect it from viral and bacterial contamination.

Hours before the hearing began, the committee’s staff released confidential audits previously reported by The Times that cited repeated violations of manufacturing standards. A leading federal manufacturing expert reiterated these concerns in a June 2020 report, warning that Emergent did not have trained staff and adequate quality control in place.

“My teenage son’s room gives your facility a run for its money,” Representative Raja Krishnamoorthi, Democrat of Illinois, told Mr. Kramer.

Mr. Kramer initially stated that the contamination of the Johnson & Johnson cans “was identified by our quality control procedures and checks and balances.” However, when questioned, he admitted that a Johnson & Johnson laboratory in the Netherlands had picked up the problem. Johnson & Johnson hired Emergent to manufacture its vaccine and is now claiming greater control over the facility at the urging of the Biden government.

The federal government placed a $ 628 million contract with Emergent last year, primarily to reserve space at the Baltimore plant for vaccine manufacturing. The legislature is examining, among other things, whether the company is maintaining its contacts with a leading representative of the Trump administration, Dr. Robert Kadlec, used to secure this mandate and whether federal officials have ignored known shortcomings in placing the work on Emergent.

Mr El-Hibri told lawmakers that the government and Johnson & Johnson are aware of the risks.

“Everyone was open-minded that this is a facility that has never manufactured a licensed product before,” he said. While the Baltimore plant was “not in perfect working order – far from it,” he argued that the plant was “in the highest state of readiness” among the plants that the government had to choose from.

For Republicans, including Mr Scalise, Wednesday’s session became a means of defending Emergent and the Trump administration and raising other virus-related issues: the unproven theory that the coronavirus leaked from a laboratory in China that “Lies of the Communist Party” of China “, mask mandates and the demand of the Biden government for a renunciation of an international agreement on intellectual property.

“You are a reputable company that did Yeoman’s job protecting this bio-defense country,” exclaimed Mark E. Green, Republican of Tennessee, adding, “So you have your people a bonus for their incredible work given. “

Emergent is able to work in Washington. The board of directors is made up of former government officials, and Senate lobbying data shows the company has spent an average of $ 3 million a year on lobbying over the past decade. That’s roughly the equivalent of two pharmaceutical giants, AstraZeneca and Bristol Myers Squibb, whose annual sales are at least 17 times higher.

Democrats urged Mr. Kramer and Mr. El-Hibri to open their contacts with Dr. Kadlec, who had previously consulted for Emergent. Documents indicate that Emergent agreed to pay him $ 120,000 annually for his advisory work between 2012 and 2015 and that he recommended that Emergent be given a “priority rating” so that the contract can be approved quickly. Dr. Kadlec said he didn’t negotiate the deal but signed it.

“Did you or any other Emergent executives speak or make contacts with Dr. Kadlec while these contracts were being issued?” Representative Nydia M. Velázquez, Democrat of New York, asked Mr. Kramer.

“Congressman,” he replied cautiously, “I haven’t had any discussions with Dr. Kadlec about it.”

The government has paid Emergent $ 271 million to date, although American regulators have not yet approved a single dose of vaccine made in the vaccine in Baltimore.

An investigation by the Times found that Emergent was an oversized influence on the Strategic National Stockpile, the country’s emergency medical reserve. In a few years, the company’s anthrax vaccine made up half of the inventory budget.

The investigation found that some federal officials believed the company was undermining taxpayers – an issue that also surfaced at Wednesday’s hearing when New York Democrat Carolyn B. Maloney asked how much it would cost to make the vaccine and what he sells for. Mr. El-Hibri promised to provide the information later.

Company executives also consider their coronavirus work to be one of the “main drivers” of 2020 revenue, according to a memorandum released Wednesday by committee staff. Executives have been rewarded for what the company’s board of directors calls “exemplary overall company performance for 2020 , including a significant overachievement of the sales and earnings targets ”.

Mr Kramer received a $ 1.2 million cash bonus in 2020, the records show, and this year also sold $ 10 million worth of shares in stores that he said were planned in advance and dated Companies have been approved. Three of the company’s executive vice presidents received awards between $ 445,000 and $ 462,000.

Sean Kirk, who is responsible for overseeing development and manufacturing processes at all Emergent production sites, received a special bonus of $ 100,000 last year in addition to his regular bonus of $ 320,611, including for expanding the contract manufacturing capacities of the Company to Covid- 19 show the documents. Mr. Kirk is now on personal vacation.

Aspiring officials “appear to have wasted tax dollars while filling their own pockets,” accused Ms. Maloney.

Mr Krishnamoorthi asked Mr Kramer if he would consider giving his bonus to American taxpayers.

“I will not make this commitment,” replied Mr. Kramer.

“I didn’t think so,” replied Krishnamoorthi-san.

Rebecca R. Ruiz contributed to the coverage.

Categories
Business

Staff at plant that ruined hundreds of thousands of J&J Covid vaccine doses did not bathe, change garments

Employees at plant that ruined millions of J&J Covid vaccine doses failed to shower, change clothes

Employees work in a laboratory at Emergent Biosolutions in Baltimore, Maryland on February 8, 2021.

Michael Robinson Chavez | The Washington Post | Getty Images

Some employees at the Emergent BioSolutions Baltimore plant were unable to shower or change clothes, which is necessary to work at the factory, and it likely helped ruin millions of Covid-19 cans from Johnson & Johnson’s key committee.

Inspections of the Bayview facility carried out last year also revealed mold problems, poor disinfection of facility equipment and inadequate staff training, employees of the selected coronavirus crisis subcommittee said in the memo. The committee is holding a hearing on Wednesday examining the biopharmaceutical company’s role in the destruction of the J&J recordings.

Although inspectors found poor conditions at the plant, top executives received hundreds of thousands of dollars in bonuses last year and were commended for their leadership by the company’s board of directors. This is evident from other documents published by the committee.

According to one document, aspiring CEO Robert Kramer received a bonus of $ 1.2 million last year, while three other executives received payments of more than $ 400,000.

The U.S. government awarded the company a $ 628 million contract to manufacture coronavirus vaccines last year.

Emergent did not immediately respond to CNBC’s request for comment.

Wednesday’s hearing comes more than a month after the Biden government hired J&J to run the Baltimore plant after US officials learned that Emergent, a federal company that makes key ingredients for J&J and AstraZeneca had produced contaminated contaminated ingredients for the two shots.

During the hearing, Kramer said the FDA is holding over 100 million J&J Covid-19 vaccine doses for further testing.

“There are a significant number of doses that we have manufactured. Here, too, we manufacture the mass drugs,” Kramer told the legislature. “It has been reported by a number of news outlets that there are likely over 100 million doses of the J&J vaccine we make that are now under FDA review for possible release and availability.”

An inspection by the Food and Drug Administration later revealed that the facility was unsanitary and unsuitable for making the shots. In a 13-page report, the inspectors wrote that the facility used to manufacture the vaccine “was not kept in a clean and sanitary condition” and “was not of the appropriate size, design and location for cleaning, maintenance and to facilitate proper operation. “”

FDA inspectors said they observed paint peeling in multiple areas and damaging walls, which could affect “Emergent’s ability to adequately clean and disinfect”. They also found that when handling waste or materials used to make vaccines, employees did not follow standard operating procedures to ensure they were not contaminated.

The facility has not been approved by the FDA to manufacture or distribute Johnson & Johnson’s Covid-19 vaccine, and none of the factory-made doses have been marketed for use in the United States. Emergent has agreed to cease production of materials until the issues identified by the FDA are resolved.

Emergent said at the time it was required to work with the FDA and J&J to resolve the issues.

“While we are never satisfied with defects in our production facilities or processes, these can be corrected and we will take quick action to correct them,” it said in a statement on April 21.

Categories
Politics

Over 100 Million Johnson & Johnson Covid Vaccine Doses on Maintain

Over 100 Million Johnson & Johnson Covid Vaccine Doses on Hold

The House Democrats launched a full investigation into Emergent after the New York Times documented months of problems at the plant, including a failure to properly disinfect equipment and protect it from viral and bacterial contamination. The committee released a series of confidential audits previously reported by The Times that identified a number of violations of manufacturing standards, as well as a June 2020 report from a leading federal manufacturing expert stating that Emergent did not have had trained staff and adequate quality control systems.

Lawmakers are looking to see if corporate officials used ties with the Trump administration to win a $ 628 million federal contract and whether Emergent executives accepted the award despite known shortcomings. You’ll also see Mr. Kramer’s sale of $ 10 million worth of Emergent stock this year and hundreds of thousands of dollars in cash awards made by Emergent’s board of directors to its top executives.

New York Democrat Representative Carolyn Maloney complained that aspiring officials “appeared to have wasted tax dollars while filling their own pockets”. Mr Krishnamoorthi sharply asked Mr Kramer if he would consider handing over his $ 1.2 million bonus to American taxpayers from 2020 onwards.

“Congressman, I will not make that commitment,” replied Mr. Kramer evenly.

“I didn’t think so,” replied Krishnamoorthi-san.

Regarding his stock deals, Mr. Kramer said they were “done according to a plan approved by the company” and in “a quiet time that was also approved by the company”. He added, “My participation has been completely removed from these stores.”

At the beginning of the hearing, Mr. Kramer testified that possible contamination of the Johnson & Johnson cans “has been identified by our quality control procedures, as well as by controls and deliberations. However, when questioned, he later admitted that it was picked up from a Johnson & Johnson laboratory in the Netherlands.

While the Democrats were pushing Mr Kramer for information about how vaccines are made, the Republicans tried to defend the company and tried to change the subject by talking about the unproven theory that the coronavirus emerged from a laboratory in China, the “Lies of the Communist Party of China” and masked mandates as well as the demand of the Biden government for a renunciation of an international agreement on intellectual property, which is strongly rejected by the pharmaceutical industry.

“You are a reputable company that did Yeoman’s job protecting this land on biological defense!” Tennessee Republican Representative Mark Green once exclaimed, adding, “So you gave your people a bonus for their incredible work.”

Categories
Business

Emergent CEO says FDA is holding over 100 million J&J Covid vaccine doses for additional testing after botched doses

Emergent CEO says FDA is holding over 100 million J&J Covid vaccine doses for further testing after botched doses

Robert Kramer, CEO of Emergent BioSolutions

Scott Mlyn | CNBC

The FDA is holding over 100 million vaccine doses of Johnson & Johnson Covid-19 for further testing after the agency found multiple security breaches at the Emergent BioSolutions facility that helped make the gunshots, said Robert Kramer, CEO of Emergent, on Wednesday to lawmakers.

The US hired J&J to run the Baltimore facility last month after learning that Emergent, a federal company that made key ingredients for J&J and AstraZeneca, contaminated the two shots. Kramer testified before House lawmakers Wednesday that the conditions at the Baltimore plant allegedly were responsible for the destruction of millions of J&J Covid-19 shots.

During the hearing before the House Select Coronavirus Crisis Subcommittee, Rep. Steve Scalise, R-La., Kramer asked how many doses of J&J vaccine are held by the Food and Drug Administration but are not contaminated.

“There are a significant number of doses that we have made. Again we are making the mass drugs,” Kramer told lawmakers. “It has been reported by a number of news outlets that there are likely over 100 million doses of the J&J vaccine we make that are now under FDA review for possible release and availability.”

Kramer later stated that the regulator requested additional testing of the cans.

“The FDA, to the best of my knowledge, evaluates the doses made for mass drug use, most of which were provided to J&J,” Kramer said. “As far as I know, there was a request for additional testing on all of these lots and doses that J&J had made available to the FDA. And they are currently being evaluated.”

J&J declined to comment on the number of doses. The FDA did not immediately respond to a request for comment.

This is a developing story. Please try again.

Categories
Business

Why Covid vaccine producer India faces main scarcity of doses

Why Covid vaccine producer India faces major shortage of doses

People aged 18 and over waiting to be vaccinated against Covid-19 at a vaccination center on the Radha Soami Satsang site operated by BLK Max Hospital on May 4, 2021 in New Delhi, India.

Hindustan Times | Hindustan Times | Getty Images

With the devastating second wave of the coronavirus pandemic in India, questions are being asked how the country where the world’s largest vaccine maker is based got to this tragic point.

India continues to report massive numbers of new infections. Tuesday passed the grim milestone of having reported over 20 million Covid cases and at least 226,188 people have died from the virus, although the reported death toll is believed to be lower than the real death toll.

Meanwhile, India’s vaccine program is struggling to make an impact and supplies are problematic, despite the country halting vaccine exports in March to focus on domestic vaccination.

The sharp rise in infections in India since February has been attributed to permission for a major religious festival and election campaigns, as well as the spread of a more contagious variant of the virus. Prime Minister Narendra Modi and his ruling Bharatiya Janata party have been criticized for a lack of caution and willingness, and accused of placing politics and campaigning above public safety.

There was also a war of words over the government’s vaccination strategy. The ruling legislature has been criticized for allowing millions of cans to be exported earlier this year.

So far India has administered around 160 million doses of a coronavirus vaccine (the predominant shots used are the AstraZeneca vaccine, made locally as Covishield, as well as a domestic vaccine developed by Bharat Biotech called Covaxin). Russian vaccine Sputnik V was approved for use in April and the first batch of doses arrived in early May, although it has not yet been used.

So far, only 30 million people in India have received full two doses of a Covid vaccine, government data shows. That is a small number (just over 2 %%) of India’s total population of 1.3 billion people – although around a quarter of that population is under the age of 15 and as such cannot yet receive a vaccine.

As of May 1, everyone aged 18 and over has been eligible for a Covid vaccine, although this expansion of the vaccination program has been hampered by dose constraints across the country reported by national media across the country.

People get their Covid-19 vaccines from medical professionals at a vaccination center set up in the classroom of a state school in New Delhi, India on May 4, 2021.

Getty Images | Getty Images News | Getty Images

Dr. Chandrakant Lahariya, a New Delhi-based doctor who is also an expert on vaccines, public policy and health systems, told CNBC on Wednesday that India’s large adult population is making vaccination efforts difficult.

“Even if the proposed supply was available, India opened vaccination to a far larger population than any vaccine framework can possibly expect. This is essentially the result of limited supply and a vaccination policy that ignores supply becomes.” No forward planning could have ensured the kind of care that is needed now with the opening of vaccination for 940 million people in India, “he said.

It is “unlikely that vaccine supplies will change drastically,” Lahariya said. “India takes between 200 and 250 million doses per month to reach full capacity of the Covid-19 vaccine engines and it has around 70 to 80 million doses per month. It is clear that there is a long way to go to get these Kind of care to achieve. ” ,” he noticed.

Vaccine wars

The shortcomings in vaccine supply have inevitably led to a diversion of blame with vaccine manufacturers in the line of fire. Questions about vaccine prices, production capacity and the destination of shipments have preoccupied the world’s largest vaccine manufacturer, Serum Institute of India, and Bharat Biotech, the Hyderabad-based pharmaceutical company that makes Covaxin.

Both had criticized their vaccine price structures (i.e. different prices for doses intended for central government, state governments and private hospitals), which prompted the CEO of the SII to lower prices later as part of a public backlash.

Adar Poonawalla, CEO of the SII, which makes the Covid vaccine developed by AstraZeneca and Oxford University, said Sunday the institute had been blamed for a vaccine shortage and scapegoated by politicians, but said it was due to capacity an initial did not increase sooner lack of orders.

“I have been a very unfair and unjustified victim,” he told the Financial Times on Monday, adding that he had not increased capacity earlier because “there were no orders, we didn’t think we were more than 1 billion Doses a year. “

Poonawalla noted that the Indian government ordered 21 million doses of Covishield from the Serum Institute in late February, but did not specify when or if it would buy more, and ordered an additional 110 million doses in March as infections began to rise.

People wearing protective face masks wait to receive a dose of Covishield, a coronavirus vaccine made by the Serum Institute of India, at a vaccination center in New Delhi, India on May 4, 2021.

Anadolu Agency | Anadolu Agency | Getty Images

Poonawalla said Indian authorities did not expect to face a second wave of cases and, as such, were not prepared for the onslaught of new infections in late winter.

He said the shortage of vaccine doses in the country will continue until July, when production is expected to increase from around 60 to 70 million doses per month to 100 million.

For its part, the Indian government insists on ordering more vaccines to meet demand. On Monday the government issued a statement rejecting media reports claiming it had not placed new orders for Covid vaccines since March, stating that “these media reports are completely false and not based on facts” . It said it had provided money to both SII and Bharat Biotech for vaccines, which are due to be delivered in May, June and July.

On Tuesday, Poonawalla issued a statement attempting to calm tensions between the government and SII. He stated that “the production of vaccines is a specialized process and it is therefore not possible to ramp up production overnight”.

“We also need to understand that India’s population is huge and it is not an easy task to produce enough doses for all adults … We have been working with the Indian government since April last year. We have all kinds of support, be it scientific , regulatory and financial, “he said. Poonawalla said the SII has received total orders over 260 million cans without disclosing buyers.

When asked if the government had misunderstood its approach to vaccine sourcing and production, Lahariya noted that the government had become complacent, even though it was difficult to predict the course of the pandemic.

“To be fair, I think there were two surprises. Unlike a year ago when the availability of Covid-19 vaccines was projected around mid-2021, the vaccine became available a little earlier. Second, the lull in Covid-19- Cases in India has ceased complacency at all levels, “he noted. Lahariya added that many months were spent prioritizing the target population for vaccination, then opening the program “too early” to all adults.

“It was an issue of hasty and arguably politically influenced planning, while it was essentially supposed to be a public health decision. So a written plan detailing various aspects, such as the forecast of care, could have made all the difference. “

Modi’s future

How the vaccination strategy will affect Modi’s ratings over the long term remains to be seen. However, there is already evidence that Modi’s ruling BJP will have to pay for the Covid crisis in the elections.

Modi’s party failed to win the key state of West Bengal in a regional election last weekend and failed to win three other state elections in April, despite retaining power in the state of Assam.

Dr. Manali Kumar of the Department of Political Science at the University of St. Gallen in Switzerland noted: “This second wave is a disaster caused by the complacency of the Indian government, which is now preoccupied with controlling the narrative rather than addressing the problem. ” “”

“Perhaps the worst disaster currently unfolding in India could have been avoided if restrictions on public and private gatherings had remained in place,” she noted, adding that “decades of neglect of investment in health infrastructure and an electorate Those who did not do this are also to blame for prioritized public services. “

Prime Minister Modi defended the government’s vaccination strategy, telling ministers in April that “those who are in the habit of politics (playing) allow it … I have received various allegations. We cannot stop those who do this to do.” We really want to serve humanity, which we will continue to do, “he said, the Times of India reported.

He also noted that an earlier peak of infections had been controlled this past September at a time when vaccines were not available and cases and mass tests were being tracked and followed.